NCT06954246 - A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

April 30, 2028

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

MHB088C for Injection

2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle

DRUG

Topotecan

1.25 mg/m\^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle

DRUG

Irinotecan

65 mg/m\^2 intravenous dose on Day 1 and Day 8 of each 21-day cycle

DRUG

Paclitaxel

135 mg/m\^2 intravenous dose on Day 1 of each 21-day cycle

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY